GRAS Notices
-
GRN No. 1145
β-lactoglobulin produced by Aspergillus oryzae strain Ao_st0002
| Intended Use: | Intended for use as a source of protein at levels ranging from 5 to 35 % in meal replacements and supplements, powdered nutritional beverages, electrolyte-sports drinks, high protein performance nutritional beverages, and nutritional bars; milk and milk substitutes, milk drinks, yogurt and fermented milk products, creams and cream substitutes, cheeses, spreads and dips, dairy-based frozen desserts and mixes; desserts and mousses; confections, coatings and fillings; baked goods; salad dressings, minor main entrée sauces; and egg substitutes. |
|---|---|
| Basis: | Scientific procedures |
| Notifier: | Imagindairy Ltd. |
| Notifier Address: |
Nahum Het St 7, Tirat Carmel 3508504 Israel |
| GRAS Notice (releasable information): | GRN 1145 (in PDF) (3.9 MB) |
| Part 2: | GRN 1145 amendments (1.4 MB) |
| Date of closure: | Dec 18, 2023 |
| FDA's Letter: | FDA has no questions (in PDF) (236 kB) |
-
